Tislelizumab
Tislelizumab
Tislelizumab (pronounced tis-lel-iz-u-mab) is a humanized monoclonal antibody designed for the treatment of solid tumors and hematologic malignancies. It is a type of immunotherapy that works by blocking the PD-1 pathway, thereby enhancing the body's immune response against cancer cells.
Etymology
The name "Tislelizumab" is derived from the International Nonproprietary Names (INN) system, which is used to name pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the "tis-" prefix is arbitrary and does not carry a specific meaning.
Mechanism of Action
Tislelizumab binds to the PD-1 receptor on T cells, blocking the interaction with its ligands, PD-L1 and PD-L2. This prevents the activation of the PD-1 pathway, which can suppress the immune response. By blocking this pathway, Tislelizumab enhances the body's immune response against cancer cells.
Clinical Use
Tislelizumab is used in the treatment of various types of cancer, including non-small cell lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma. It is also being investigated for use in other types of cancer.
Related Terms
- Monoclonal antibody
- Immunotherapy
- PD-1
- PD-L1
- PD-L2
- Non-small cell lung cancer
- Hepatocellular carcinoma
- Esophageal squamous cell carcinoma
External links
- Medical encyclopedia article on Tislelizumab
- Wikipedia's article - Tislelizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski